BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Muparfostat: SPA submitted

Progen said partner Medigen submitted an updated SPA to FDA for a planned placebo-controlled, international Phase III trial to evaluate PI-88 in 500 patients. Medigen plans to start the trial by year end. In 2008, Progen discontinued the Phase...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >